Healthcare startup Neuranics has raised $700,000 in a seed funding round led by Inflection Point Ventures (IPV).
The funds will be utilized to further develop the company’s diagnostic technology, conduct clinical trials, and prepare for commercial production following regulatory approval from India’s Central Drugs Standard Control Organisation (CDSCO).
About Neuranics:
Founded in 2021 by Praveen Kumar and Ashutosh Patra, Neuranics is developing a portable blood analyzer capable of delivering complete blood count (CBC) results in under 10 minutes using just a finger-prick sample.
The device is designed for primary care and emergency settings, offering low-maintenance, high-efficiency diagnostic capabilities to improve patient outcomes.
Also Read: Medial Raises $500K in Pre-Series A Funding
The startup combines precision robotics, advanced imaging, and microfluidics to pioneer this innovation. It has already received a patent, a CDSCO Test License, and Ethical Approval from AIIMS Delhi and is progressing with clinical trials.
“We are re-imagining how we approach diagnostics by bringing instant, accurate blood analysis closer to the patient without compromising on the quality,” said Kumar, Co-founder and CEO of Neuranics.
He emphasized the impact of the technology on accelerating treatments for critical conditions such as sepsis, severe anemia, and thrombocytopenia, particularly in cases of dengue fever.
Neuranics operates in the diagnostics industry, where the global CBC market is projected to reach $50 billion, growing at an annual rate of 8-10%.
